XSHE
002793
Market cap723mUSD
Jul 10, Last price
4.60CNY
1D
2.00%
1Q
-8.55%
Jan 2017
-75.14%
IPO
-12.93%
Name
Luoxin Pharmaceuticals Group Stock Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Luoxin Pharmaceuticals Group Stock Co., Ltd. is a Chinese pharmaceutical enterprise, primarily focused on the research, development, manufacture, and commercialization of pharmaceutical products. Headquartered in Linyi, the company offers an extensive portfolio of active pharmaceutical ingredients (APIs) and intermediates. These key components cater to a wide array of therapeutic areas, including antiviral and anti-infective treatments, respiratory and digestive system disorders, nervous and endocrine system conditions, cardiovascular health, oncology, and anti-allergy medications. Additionally, it supplies APIs and intermediates for antipyretic, analgesic, and anti-inflammatory drugs. Beyond its core pharmaceutical activities, Luoxin Pharmaceuticals also ventures into the provision of medical treatment and broader health services. The company adopted its current name, Luoxin Pharmaceuticals Group Stock Co., Ltd., in April 2020, having previously operated as Zhejiang Doyin Pump Industry Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||